Name

Regor Therapeutics

Legal name

Regor Therapeutics Group

Website

https://regor.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Out-licensing and asset sales: Regor out-licenses its proprietary drug candidates to large pharmaceutical companies for late-stage development and commercialization. Revenue comes from upfront payments, milestone payments, and royalties on net sales. Example: $850M upfront deal with Roche/Genentech for CDK inhibitor portfolio.
2. Clinical development partnerships: Strategic collaborations with pharmaceutical partners for co-development of pipeline candidates through clinical stages, generating milestone payments and potential future royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Regor Therapeutics is a clinical-stage biotechnology company that discovers and develops proprietary small molecule drug candidates in oncology, metabolism, and immunology using its proprietary rCARD drug discovery platform. The company advances candidates through preclinical and early clinical stages, then out-licenses or sells them to large pharmaceutical partners such as Roche/Genentech for late-stage development and commercialization, generating upfront payments, milestones, and royalties.

Product overview

Regor Therapeutics Group is a clinical-stage biotechnology company that operates as a drug discovery engine powered by its proprietary rCARD (Computer Accelerated Rational Discovery) platform. The company develops a pipeline of pre-clinical and clinical candidates across three therapeutic areas: metabolism, oncology, and immunology. The core products include RGT-075, a once-daily oral small molecule GLP-1R agonist for obesity in Phase II trials, and a portfolio of next-generation CDK inhibitors (RGT-419B and RGT-587) for breast cancer that have been out-licensed to Roche/Genentech. The rCARD platform integrates computational biology, structural biology, and computational chemistry to discover and optimize pre-clinical candidates before licensing to top pharmaceutical partners for clinical development and commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

• RGT-419B (GDC-4198) Next-generation CDK inhibitor for breast cancer, targeting HR+/HER2- advanced breast cancer patients who have progressed on CDK4/6 inhibitors and endocrine therapy. Licensed to Roche/Genentech with Phase I trials in progress.
• RGT-587 (GDC-0587) Next-generation CDK inhibitor for breast cancer, part of the next-generation CDK inhibitor portfolio out-licensed to Roche/Genentech. Phase I trials in progress.
• RGT-075 Once-daily oral small molecule GLP-1R agonist for the treatment of obesity and type 2 diabetes, demonstrating peptide-like efficacy and tolerability. Phase II trials in progress.
• rCARD Platform Regor Computer Accelerated Rational Discovery (rCARD) platform that combines computational biology, structural biology, and computational chemistry for target identification, validation, and molecule design and optimization. Powers Regor's preclinical candidate discovery across metabolism, oncology, and immunology.
• RGT-068A Preclinical MALT1 inhibitor developed using proprietary chemistry (direct construction of chiral ether via Heck reaction and N-directed asymmetric hydrogenation). Targeted at immunology/autoimmune indications.
• QR-6401 Macrocyclic CDK2 inhibitor discovered through generative models and structure-based drug design as a preclinical oncology asset.

Quantifiable outcome

• Phase 2a topline results achieved for RGT-075 in obesity treatment
• +2 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Two partnerships are on record, tiered core and flagship.

• SermonixcoreStrategic or Co-development Partner · 24 March 2025Strategic collaboration to optimize Regor's proprietary rCARD platform for identification of novel targets and therapeutics. Sermonix and Regor are working together to advance the rCARD platform capabilities.
• Genentech (Roche)flagshipOEM/ Whitelabel/ Licensing Partner · 30 September 2024Regor entered into a definitive purchase agreement for Genentech to acquire Regor's portfolio of next-generation CDK inhibitors (RGT-419B/GDC-4198 and RGT-587/GDC-0587) for breast cancer treatment. Deal valued at $850M upfront payment with potential additional milestones.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Structure Therapeutics: Clinical-stage biotech developing oral small molecule GLP-1R agonists for obesity and metabolic disease — the closest direct competitor to Regor's RGT-075 program, sharing the same differentiated oral-GLP-1 thesis and target patient population.
• Schrödinger, Inc. Operates a computational drug discovery platform (LiveDesign) used by multiple pharma partners — comparable to Regor's rCARD platform in combining physics-based simulation, ML, and structural biology to accelerate small molecule discovery and partnering.
• Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with computational methods to generate a broad preclinical and clinical pipeline — analogous to Regor's platform-driven, asset-out-licensing model across multiple therapeutic areas.
• Exscientia: AI-based drug discovery company using a precision design platform to advance partnered and wholly-owned candidates — shares Regor's platform-as-engine approach and reliance on pharma out-licensing/collaboration revenue.
• Relay Therapeutics: Precision medicine biotech integrating computational methods (DYNAMO platform) with structural biology to develop targeted oncology therapies — comparable to Regor's rCARD-driven approach in oncology and CDK-targeted programs.
• Terns Pharmaceuticals: Clinical-stage biotech with a pipeline spanning obesity (oral GLP-1RA) and oncology — a direct competitor to Regor's RGT-075 program and shares the Asia-Pacific / US cross-border operating model.

Emerging players

• Black Diamond Therapeutics: Clinical-stage precision oncology biotech using a discovery platform to develop targeted therapies against resistance mutations — comparable to Regor's focus on next-generation kinase inhibitors addressing resistance in solid tumors.
• Erasca: Clinical-stage precision oncology company developing kinase inhibitors for RAS/MAPK pathway cancers — overlaps with Regor's CDK inhibitor portfolio in oncology target class and clinical-stage out-licensing dynamic.
• Frontier Medicines: Early-stage platform biotech using chemoproteomics and computational chemistry to drug challenging targets — comparable to Regor in scale, platform-driven discovery approach, and partnership-oriented pipeline strategy.

Broad incumbents

• Arvinas: Clinical-stage biotech with a broader targeted protein degradation platform and multiple pharma partnerships — comparable in business model (platform + partnered pipeline) but addresses different target classes than Regor's CDK and GLP-1 programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/regor-therapeutics-group

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regor Therapeutics